Drug Profile

AR 201 - Aimmune Therapeutics

Alternative Names: AR 201 - food allergy OIT - Aimmune Therapeutics; AR 201 - food allergy oral immunotherapies - Aimmune Therapeutics; AR-201- Aimmune Therapeutics; AR201; Egg allergy - Aimmune Therapeutics; Egg allergy immunotherapy - Aimmune Therapeutics

Latest Information Update: 29 Jun 2021

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Aimmune Therapeutics
Class Allergens; Antiallergics; Food allergy immunotherapies
Mechanism of Action Immunomodulators

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

Highest Development Phases

Discontinued Food hypersensitivity

Most Recent Events

14 Oct 2020 Aimmune Therapeutics has been acquired by Nestle
31 Jul 2019 Phase-II clinical trials in Food hypersensitivity (In children, In adolescents, In adults) in USA (PO) (NCT04056299)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight